Amarin Corp Plc (AMRN)

[Biwatch]

R-It – interim results and financing

Whalatane,
About possible interim results and financing, I suggest you to read or re-read the transcript of the Goldman Sachs conference of June 12th, 2014.
http://seekingalpha.com/article/2264943-amarin-corporation-plcs-ceo-presents-at-goldman-sachs-2014-global-healthcare-conference-transcript?page=2&p=qanda&l=last

Before this conf call, the message of Amarin was “…FDA is aware that without Anchor, we can't continue Reduce-it in its actual form. There is a range of possibilities…”
I have always thought that one of these possibilities was to stop the study earlier than forecast, hoping for a better efficacy than 15%.
During this conf call, It was the first time I heard Amarin suggesting this possibility. Quote from JT:” You know, one of the things that could potentially be done is that there's a, you know, there is the existing 60% interim look. One could look at other opportunities for interim looks. We know that from the JELIS study in Japan, that about a year and a half into that study, that the controlled group versus the active arm began to separate meaningfully. We have no visibility into the current study as to whether that would be the truth here or not. But we can certainly look at those types of opportunities for potential ways getting to a result faster.”

Biwatch